MINI FUTURE LONG - GENMAB | Market Closed - Deutsche Boerse AG 15:21:01 28/06/2024 BST | ||
| 6.26 EUR | -8.35% |
|
| Current month | -23.86% | ||
| 1 month | -24.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 6.26 | -8.35% |
| 27/06/24 | 6.83 | -0.73% |
| 26/06/24 | 6.88 | -1.57% |
| 25/06/24 | 6.99 | -1.41% |
| 24/06/24 | 7.09 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 03:21 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
BNP Paribas
|
| WKN | PX2CPU |
| ISIN | DE000PX2CPU1 |
| Date issued | 30/07/2019 |
| Strike | 1,281 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.25 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 29.3 € |
|---|---|
| Lowest since issue | 1.03 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,745
DKK
Average target price
2,464
DKK
Spread / Average Target
+41.20%
- Stock Market
- Certificates
- Certificat
